Stockreport

Kura Oncology Announces Presentation of Preliminary Clinical Data for Tipifarnib in HRAS Mutant Squamous Cell Carcinomas of the Head and Neck at TAT 2017

Kura Oncology, Inc.  (KURA) 
Last kura oncology, inc. earnings: 2/25 04:03 pm Check Earnings Report
US:NASDAQ Investor Relations: ir.kuraoncology.com/investor-relations
PDF LA JOLLA, Calif., Feb. 27, 2017 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq:KURA), a clinical stage biopharmaceutical company, today announced an oral presentation [Read more]